Compile Data Set for Download or QSAR
Report error Found 330 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-18,20-1210,C797S]'
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717429(3-{3-(4-fluorophenyl)-4-[6-(1- methyl-1H-pyrazol-4...)
Affinity DataIC50: 0.0500nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717350(3-[3-(4-fluorophenyl)-4-(8- phenyl-9H-purin-6-yl)-...)
Affinity DataIC50: 0.0600nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717395(3-{3-(4-fluorophenyl)-4-[6-(1H- imidazol-4-yl)furo...)
Affinity DataIC50: 0.0600nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717425((1S,3S)-3-[3-(4-fluorophenyl)-4- (6-phenylfuro[2,3...)
Affinity DataIC50: 0.0600nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717455(1-{3-(4-fluorophenyl)-4-[6-(5- methoxypyridin-2-yl...)
Affinity DataIC50: 0.0700nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717208(3-[4-(4-fluorophenyl)-5-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.0770nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717444(3-{3-(4-fluorophenyl)-4-[6-(1- methyl-1H-imidazol-...)
Affinity DataIC50: 0.0780nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717448(3-{3-(4-fluorophenyl)-4-[6- (pyridin-2-yl)furo[2,3...)
Affinity DataIC50: 0.0820nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717306(3-[3-(4-fluorophenyl)-4-(8- phenyl-9H-purin-6-y1)-...)
Affinity DataIC50: 0.0900nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717426((1R,3R)-3-[3-(4-fluorophenyl)-4- (6-phenylfuro[2,3...)
Affinity DataIC50: 0.0900nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717431(1-{3-(4-fluorophenyl)-4-[6- (1,3,5-trimethyl-1H-py...)
Affinity DataIC50: 0.0900nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717197(3-[4-(4-fluorophenyl)-5-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.0930nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717445(2,2-difluoro-3-{3-(4- fluorophenyl)-4-[6-(1-methyl...)
Affinity DataIC50: 0.0940nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717438(4-{3-(4-fluorophenyl)-1-[(1s,3s)- 3-(methanesulfon...)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717447(3-{3-(4-fluorophenyl)-4-[6- (pyridin-3-y1)furo[2,3...)
Affinity DataIC50: 0.104nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717458((1r,3r)-3-{4-[6-(1,3-dimethyl- 1H-pyrazol-4-yl)fur...)
Affinity DataIC50: 0.106nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717273(2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.110nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717352(3-{3-(4-fluorophenyl)-4-[6- (pyridin-2-yl)furo[2,3...)
Affinity DataIC50: 0.110nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717384(3-[3-(4-fluorophenyl)-4-(6-{3- [(4-methylpiperazin...)
Affinity DataIC50: 0.110nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717433(1-{3-(4-fluorophenyl)-4-[6-(1- methyl-1H-imidazol-...)
Affinity DataIC50: 0.110nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717189(3-[3-(4-fluorophenyl)-4-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.113nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717462(3-{4-[3-(4-fluorophenyl)-1-(2- hydroxy-2-methylpro...)
Affinity DataIC50: 0.113nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717212(3-[3-(4-fluorophenyl)-4-{6-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.119nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717299((1s,3s)-3-(3-(4-fluorophenyl)-4- (6-phenylfuro[2,3...)
Affinity DataIC50: 0.120nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717309(1-[3-(4-fluorophenyl)-4-(8- phenyl-9H-purin-6-yl)-...)
Affinity DataIC50: 0.120nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717188(3-[3-(4-fluorophenyl)-4-(6- phenyl-7H-pyrrolo[2,3-...)
Affinity DataIC50: 0.121nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717457((1r,3r)-3-{3-(4-fluorophenyl)-4- [6-(1-methyl-1H-i...)
Affinity DataIC50: 0.123nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717282(N-{2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]py...)
Affinity DataIC50: 0.130nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717379(3-{3-(4-fluorophenyl)-4-[6-(1- methyl-1H-imidazol-...)
Affinity DataIC50: 0.130nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717443(4-{1-[(1s,3s)-3- fluorocyclobutyl]-3-(4- fluorophe...)
Affinity DataIC50: 0.135nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717300((1r,3r)-3-(3-(4-fluorophenyl)-4- (6-phenylfuro[2,3...)
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717340(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717362(2-{4-[1-(1,1-dioxo-1lambda6-thietan- 3-yl)-3-(4-fl...)
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717382(N-(3-{4-[1-(1,1-dioxo-126- thietan-3-yl)-3-(4-fluo...)
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717403(3-{3-(4-fluorophenyl)-4-[6-(2- methyl-1,3-thiazol-...)
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717186(3-[3-(4-fluorophenyl)-4-(8- phenyl-9H-purin-6-yl)-...)
Affinity DataIC50: 0.148nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717442(4-[1-(3,3-difluoropropyl)-3-(4- fluorophenyl)-1H-p...)
Affinity DataIC50: 0.153nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717415(3-{3-(4-fluorophenyl)-4-[6-(2- methyl-1,3-thiazol-...)
Affinity DataIC50: 0.160nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717437(1-{4-[6-(1,5-dimethyl-1H- pyrazol-4-yl)furo[2,3- d...)
Affinity DataIC50: 0.160nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717198(3-[3-(4-fluorophenyl)-4-{6-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717192(3-[3-(4-fluorophenyl)-4-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.173nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717237(1-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.177nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717288(1-[3-(2-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.180nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717305((3S)-3-{[3-(4-fluorophenyl)-4- (6-phenylfuro[2,3-d...)
Affinity DataIC50: 0.180nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717369(3-[3-(4-fluorophenyl)-4-(6-{3- [(morpholin-4- yl)m...)
Affinity DataIC50: 0.180nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717421(3-{4-[6-(1,3-dimethyl-1H- pyrazol-4-yl)furo[2,3- d...)
Affinity DataIC50: 0.180nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717446(1-[4-{6-[5-(difluoromethyl)-1- methyl-1H-pyrazol-4...)
Affinity DataIC50: 0.185nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717435(4-{3-(4-fluorophenyl)-1-[(1s,3s)- 3-(methanesulfon...)
Affinity DataIC50: 0.190nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717219(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.192nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717281(4-{3-(4-fluorophenyl)-1-[(3S)-1- (methanesulfonyl)...)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR exon 19 deletion/C7...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 330 total ) | Next | Last >>
Jump to: